Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti- tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data readout from Phase 1 APOLLO study expected later this year HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical- stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hemat ...